Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
Kathrin Renner(University Hospital Regensburg), Marina Kreutz(University of Regensburg), Ayse N. Menevse(Leibniz Association), Katrin Peter(University Hospital Regensburg), Matthias Fante(Universitätsklinikum Würzburg), Elisa A. Rozeman(The Netherlands Cancer Institute), Stephanie Faerber(University Hospital Regensburg), Christina Bruß(University Hospital Regensburg), Raquel Blazquez(University Hospital Regensburg), Mark Selby(Bristol-Myers Squibb (Germany)), Tobias Bopp(Johannes Gutenberg University Mainz), Maria Landa(University of Regensburg), Toszka Bohn(Johannes Gutenberg University Mainz), William Roush(Scripps Research Institute), Ibtisam Marchiq(Centre National de la Recherche Scientifique), Gudrun E. Koehl, John L. Cleveland(Moffitt Cancer Center), Annette Schnell(University Hospital Regensburg), Eva Gottfried(University of Regensburg), Holger M. Becker(Medizinische Hochschule Hannover), Lisa Hacker(University Hospital Regensburg), Oscar Krijgsman(The Netherlands Cancer Institute), Christina Brummer(University Hospital Regensburg), Philipp Beckhove(German Cancer Research Center), Sabine Amslinger(University of Regensburg), Katja Dettmer(University of California, Davis), Peter J. Oefner, Sarah Warren(Nanostring Technologies (United States)), Tobias Pukrop(University Hospital Regensburg), Sven Arke Lang(American Institute of Biological Sciences), Stefanie Pektor(Johannes Gutenberg University Mainz), Katja Evert(University Hospital Regensburg), Christian U. Blank(The Netherlands Cancer Institute), Katrin Singer(University Hospital Regensburg), Lisa Aigle(University Hospital Regensburg), Jacques Pouysségur(Inserm), Nathalie Kauer(University Hospital Regensburg), Wolfgang Herr(University Hospital Regensburg), SuFey Ong(Nanostring Technologies (United States)), Peter J. Siska(University Hospital Regensburg), Sonja-Maria Decking(University Hospital Regensburg), Matthias Miederer(Johannes Gutenberg University Mainz)
Cited by 297
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Mass spectrometry‐based metabolomics
|Mass Spectrometry Reviews|2006|2.2k
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
|Autophagy|2008|2k
Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings
|Annals of Surgery|2012|1.3k
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
|Journal of Biological Chemistry|1996|1.2k